Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 May;84(10):1301–1307. doi: 10.1054/bjoc.2001.1787

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy

M K Tuxen 1,2, G Sölétormos 3, P Dombernowsky 1
PMCID: PMC2363637  PMID: 11355938

Abstract

The value of the serum tumour marker CA 125 to date has been in the monitoring of ovarian cancer patients for response to therapy and for recurrence of disease. However, despite the availability of serial data on CA 125, the problem of interpreting a change over time is still unsolved. The aim of this study was to assess the ability of CA 125 to monitor patients with ovarian cancer during postoperative chemotherapy. 255 patients with stage IC-IV ovarian cancer were allocated to the tumour marker monitoring study. The evaluation of CA 125 information was based on the analytical imprecision, the normal intra-individual biological variation, the sampling interval, and the cut-off value. Additionally, a new assessment criterion based upon an increment of 2.5 times the baseline CA 125 concentration confirmed by a third measurement was elaborated and the utility investigated. The efficiency of CA 125 for identifying progression and non-progression during first-line chemotherapy was 91.9%. The median lead time for true positive results was 41 days. Using the new elaborated criterion the efficiency of CA 125 for identifying progression and non-progression during first-line chemotherapy was 90.5%. The median lead time for true positive results was 35 days. CA 125 gave reliable prediction of progressive disease during postoperative chemotherapy. The results indicate a high applicability of the presented progression criteria during CA 125 monitoring of patients with changing activity of ovarian cancer. © 2001 Cancer Research Campaign www.bjcancer.com

Keywords: CA 125, ovarian cancer, progression criteria, monitoring, biological variation, analytical variation

Full Text

The Full Text of this article is available as a PDF (90.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bassetto M. A., Franceschi T., Lenotti M., Pancheri F., Zaninelli M., Corgnati A., Cetto G. L. Valore della positività dei marcatori tumorali nei tumori germinali non seminomatosi del testicolo. J Nucl Med Allied Sci. 1990 Oct-Dec;34(4 Suppl):89–90. [PubMed] [Google Scholar]
  2. Bast R. C., Jr, Klug T. L., Schaetzl E., Lavin P., Niloff J. M., Greber T. F., Zurawski V. R., Jr, Knapp R. C. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol. 1984 Jul 1;149(5):553–559. doi: 10.1016/0002-9378(84)90035-8. [DOI] [PubMed] [Google Scholar]
  3. Bast R. C., Jr, Klug T. L., St John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883–887. doi: 10.1056/NEJM198310133091503. [DOI] [PubMed] [Google Scholar]
  4. Boscato L. M., Stuart M. C. Heterophilic antibodies: a problem for all immunoassays. Clin Chem. 1988 Jan;34(1):27–33. [PubMed] [Google Scholar]
  5. Collazos J., Genolla J., Ruibal A. CA 125 serum levels in patients with non-neoplastic liver diseases. A clinical and laboratory study. Scand J Clin Lab Invest. 1992 May;52(3):201–206. doi: 10.3109/00365519209088786. [DOI] [PubMed] [Google Scholar]
  6. Cruickshank D. J., Terry P. B., Fullerton W. T. CA125-response assessment in epithelial ovarian cancer. Int J Cancer. 1992 Apr 22;51(1):58–61. doi: 10.1002/ijc.2910510112. [DOI] [PubMed] [Google Scholar]
  7. Fioretti P., Gadducci A., Ferdeghini M., Bartolini T., Bianchi R., Facchini V. Correlation of CA125 and CA19-9 serum levels with clinical course and second-look findings in patients with ovarian carcinoma. Gynecol Oncol. 1987 Nov;28(3):278–283. doi: 10.1016/0090-8258(87)90173-9. [DOI] [PubMed] [Google Scholar]
  8. Fioretti P., Gadducci A., Ferdeghini M., Prontera C., Malagnino G., Facchini V., Mariani G., Bianchi R. The concomitant determination of different serum tumor markers in epithelial ovarian cancer: relevance for monitoring the response to chemotherapy and follow-up of patients. Gynecol Oncol. 1992 Feb;44(2):155–160. doi: 10.1016/0090-8258(92)90031-d. [DOI] [PubMed] [Google Scholar]
  9. Fraser C. G., Hyltoft Peterson P., Larsen M. L. Setting analytical goals for random analytical error in specific clinical monitoring situations. Clin Chem. 1990 Sep;36(9):1625–1628. [PubMed] [Google Scholar]
  10. Fraser C. G., Petersen P. H. The importance of imprecision. Ann Clin Biochem. 1991 May;28(Pt 3):207–211. doi: 10.1177/000456329102800301. [DOI] [PubMed] [Google Scholar]
  11. Gadducci A., Ferdeghini M., Ceccarini T., Prontera C., Facchini V., Bianchi R., Fioretti P. A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma. Eur J Gynaecol Oncol. 1990;11(2):127–133. [PubMed] [Google Scholar]
  12. Gadducci A., Ferdeghini M., Rispoli G., Prontera C., Bianchi R., Fioretti P. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. Scand J Clin Lab Invest Suppl. 1991;207:19–24. doi: 10.3109/00365519109104621. [DOI] [PubMed] [Google Scholar]
  13. Gard G. B., Houghton C. R. An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gynecol Oncol. 1994 Jun;53(3):283–289. doi: 10.1006/gyno.1994.1135. [DOI] [PubMed] [Google Scholar]
  14. Hising C., Anjegård I. M., Einhorn N. Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients. Am J Clin Oncol. 1991 Apr;14(2):111–114. doi: 10.1097/00000421-199104000-00003. [DOI] [PubMed] [Google Scholar]
  15. Krebs H. B., Goplerud D. R., Kilpatrick S. J., Myers M. B., Hunt A. Role of Ca 125 as tumor marker in ovarian carcinoma. Obstet Gynecol. 1986 Apr;67(4):473–477. [PubMed] [Google Scholar]
  16. Molina R., Filella X., Bruix J., Mengual P., Bosch J., Calvet X., Jo J., Ballesta A. M. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991 Aug;37(8):1379–1383. [PubMed] [Google Scholar]
  17. Nicholson S., Fox M., Epenetos A., Rustin G. Immunoglobulin Inhibiting Reagent: evaluation of a new method for eliminating spurious elevations in CA125 caused by HAMA. Int J Biol Markers. 1996 Jan-Mar;11(1):46–49. doi: 10.1177/172460089601100109. [DOI] [PubMed] [Google Scholar]
  18. Niloff J. M., Knapp R. C., Lavin P. T., Malkasian G. D., Berek J. S., Mortel R., Whitney C., Zurawski V. R., Jr, Bast R. C., Jr The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol. 1986 Jul;155(1):56–60. doi: 10.1016/0002-9378(86)90077-3. [DOI] [PubMed] [Google Scholar]
  19. Panza N., Pacilio G., Campanella L., Peluso G., Battista C., Amoriello A., Utech W., Vacca C., Lombardi G. Cancer antigen 125, tissue polypeptide antigen, carcinoembryonic antigen, and beta-chain human chorionic gonadotropin as serum markers of epithelial ovarian carcinoma. Cancer. 1988 Jan 1;61(1):76–83. doi: 10.1002/1097-0142(19880101)61:1<76::aid-cncr2820610113>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  20. Plebani M., Giacomini A., Beghi L., de Paoli M., Roveroni G., Galeotti F., Corsini A., Fraser C. G. Serum tumor markers in monitoring patients: interpretation of results using analytical and biological variation. Anticancer Res. 1996 Jul-Aug;16(4B):2249–2252. [PubMed] [Google Scholar]
  21. Ruibal A., Encabo G., Martinéz-Miralles E., Murcia C., Capdevila J. A., Salgado A., Martinéz-Vasquéz J. M. CA125 seric levels in non malignant pathologies. Bull Cancer. 1984;71(2):145–146. [PubMed] [Google Scholar]
  22. Rustin G. J., Nelstrop A. E., Crawford M., Ledermann J., Lambert H. E., Coleman R., Johnson J., Evans H., Brown S., Oster W. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. J Clin Oncol. 1997 Jan;15(1):172–176. doi: 10.1200/JCO.1997.15.1.172. [DOI] [PubMed] [Google Scholar]
  23. Rustin G. J., Nelstrop A. E., Tuxen M. K., Lambert H. E. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996 Apr;7(4):361–364. doi: 10.1093/oxfordjournals.annonc.a010602. [DOI] [PubMed] [Google Scholar]
  24. Rustin G. J., Nelstrop A., Stilwell J., Lambert H. E. Savings obtained by CA-125 measurements during therapy for ovarian carcinoma. The North Thames Ovary Group. Eur J Cancer. 1992;28(1):79–82. doi: 10.1016/0959-8049(92)90390-n. [DOI] [PubMed] [Google Scholar]
  25. Spina M., Sandri S., Serraino D., Gobitti C., Fasan M., Sinicco A., Garavelli P. L., Ridolfo A., Tirelli U. Therapy of non-small-cell lung cancer (NSCLC) in patients with HIV infection. GICAT. Cooperative Group on AIDS and Tumors. Ann Oncol. 1999;10 (Suppl 5):S87–S90. doi: 10.1093/annonc/10.suppl_5.s87. [DOI] [PubMed] [Google Scholar]
  26. Sölétormos G., Nielsen D., Schiøler V., Skovsgaard T., Dombernowsky P. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up. Clin Chem. 1996 Apr;42(4):564–575. [PubMed] [Google Scholar]
  27. Sölétormos G., Nielsen D., Schiøler V., Skovsgaard T., Winkel P., Mouridsen H. T., Dombernowsky P. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA. Ann Oncol. 1993 Dec;4(10):861–869. doi: 10.1093/oxfordjournals.annonc.a058394. [DOI] [PubMed] [Google Scholar]
  28. Sölétormos G., Schiøler V., Nielsen D., Skovsgaard T., Dombernowsky P. Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem. 1993 Oct;39(10):2077–2083. [PubMed] [Google Scholar]
  29. Thigpen T., Vance R. B., McGuire W. P., Hoskins W. J., Brady M. The role of paclitaxel in the management of coelomic epithelial carcinoma of the ovary: a review with emphasis on the Gynecologic Oncology Group experience. Semin Oncol. 1995 Dec;22(6 Suppl 14):23–31. [PubMed] [Google Scholar]
  30. Tuxen M. K., Sölétormos G., Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995 May;21(3):215–245. doi: 10.1016/0305-7372(95)90002-0. [DOI] [PubMed] [Google Scholar]
  31. Tuxen M. K., Sölétormos G., Rustin G. J., Nelstrop A. E., Dombernowsky P. Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer. Scand J Clin Lab Invest. 2000 Dec;60(8):713–721. doi: 10.1080/00365510050216448. [DOI] [PubMed] [Google Scholar]
  32. Vergote I. B., Abeler V. M., Børmer O. P., Stigbrand T., Tropé C., Nustad K. CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma. Tumour Biol. 1992;13(3):168–174. doi: 10.1159/000217761. [DOI] [PubMed] [Google Scholar]
  33. Ward B. G., McGuckin M. A., Ramm L. E., Coglan M., Sanderson B., Tripcony L., Free K. E. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays. Cancer. 1993 Jan 15;71(2):430–438. doi: 10.1002/1097-0142(19930115)71:2<430::aid-cncr2820710225>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  34. van der Burg M. E., Lammes F. B., Verweij J. The role of CA 125 in the early diagnosis of progressive disease in ovarian cancer. Ann Oncol. 1990 Jul;1(4):301–302. doi: 10.1093/oxfordjournals.annonc.a057754. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES